Scott Hutton Sells 3,559 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 3,559 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer owned 45,413 shares in the company, valued at $457,763.04. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scott Hutton also recently made the following trade(s):

• On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The shares were sold at an average price of $8.15, for a total value of $7,905.50.

Biodesix Trading Up 4.7%

NASDAQ BDSX opened at $10.84 on Friday. The company has a market cap of $86.29 million, a P/E ratio of -1.95 and a beta of 0.67. Biodesix, Inc. has a 12 month low of $3.44 and a 12 month high of $20.40. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. The company has a 50-day moving average of $8.39 and a 200-day moving average of $7.98.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on BDSX shares. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Biodesix currently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix News Roundup

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Reported reduction in month‑end short interest (late Jan) meaningfully lowered days‑to‑cover and near‑term short pressure — a supportive technical factor if sustained.
• Neutral Sentiment: Biodesix will report Q4 and full‑year 2025 results after market close on Feb. 26 and host a 4:30pm ET conference call/webcast for a business update. Investors should listen for revenue, margin, cash‑flow and any guidance or commentary on test uptake (Nodify Lung, IQLung). Earnings Release
• Neutral Sentiment: February short‑interest data show anomalous “0 shares” figures for Feb. 10–12; likely a reporting or exchange/data‑feed error. Treat the zero reports cautiously until corrected by exchanges or data providers.
• Negative Sentiment: CEO Scott Hutton sold 3,559 shares on Feb. 10 (~$10.08 average), reducing his stake ~7.3% — a signal that can unsettle investors even if sales are for personal reasons. CEO Form 4
• Negative Sentiment: Other senior insiders also sold on Feb. 10 (CFO Robin Harper Cowie — 941 shares; Chief Dev. Officer Gary Pestano — 540; CCO Kieran O’Kane — 584; CAO Chris Vazquez — 101). Multiple simultaneous exec sales amplify negative sentiment. CFO Form 4

Institutional Trading of Biodesix

Institutional investors have recently added to or reduced their stakes in the business. Aberdeen Group plc acquired a new stake in Biodesix in the 4th quarter valued at $1,784,000. XTX Topco Ltd boosted its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the period. Monashee Investment Management LLC grew its stake in shares of Biodesix by 12.3% in the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock valued at $764,000 after buying an additional 12,348 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after buying an additional 2,235 shares during the period. Finally, DRW Securities LLC purchased a new stake in shares of Biodesix during the 4th quarter valued at about $105,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.